Medical film

A medical film with a crosslinked polymer and biodegradable resin combination addresses the challenge of repositionability by minimizing initial swelling, allowing for easy reapplication and maintaining strength, addressing the limitations of existing films with solubility control layers.

WO2024232411A1PCT designated stage expired Publication Date: 2024-11-14KUREHA CORPORATION
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/017249
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-05-09
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Medical films used for preventing adhesions after surgery often lack repositionability due to their thickness and solubility control layers, which can make them difficult to reapply and expensive to produce.

Method used

A medical film composed of a crosslinked polymer material and a biodegradable resin, with specific volume ratios and molecular weight ranges, that swells minimally upon immersion in phosphate buffer, allowing for improved repositionability without the need for solubility control layers.

Benefits of technology

The film maintains strength and adhesion properties while being easily removable and reattachable, reducing adhesion to organs and facilitating reapplication, thus enhancing surgical procedures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-M000001
    Figure JPOXMLDOC01-APPB-M000001
  • Figure JPOXMLDOC01-APPB-M000002
    Figure JPOXMLDOC01-APPB-M000002
  • Figure JPOXMLDOC01-APPB-T000003
    Figure JPOXMLDOC01-APPB-T000003
Patent Text Reader

Abstract

Provided is a medical film capable of showing enhanced re-attachability even without forming a layer for controlling solubility. In the medical film of the present invention, the ratio q1 (V1 / V0) of the volume V1 after immersion for 10 seconds in a phosphate buffer (PB) of pH 6.0 and concentration 0.2 M to the volume V0 before the immersion is not more than 1.5.
Need to check novelty before this filing date? Find Prior Art

Description

Medical Film

[0001] The present invention relates to a medical film.

[0002] Medical films (anti-adhesion materials) are known that are applied to organs after surgery to prevent adhesion between the organ and other organs during wound healing. Anti-adhesion materials are made of bioabsorbable materials such as crosslinked hyaluronic acid and carbomethylcellulose.

[0003] Medical films, such as adhesion barriers, that are attached to organs are required to be able to adjust the attachment position and reattach after being attached to the surface of an organ. Patent Document 1 describes an adhesion barrier, as a medical film with enhanced reattachability, that has a base layer containing a water-soluble polymer and a support layer containing an aliphatic ester formed on the surface of the base layer. According to Patent Document 1, this adhesion barrier has a support layer made of a water-insoluble aliphatic ester on the surface, making it easy to handle with tweezers or the like even when wet, and easy to reattach.

[0004] Furthermore, Patent Document 2 describes an adhesion preventing material having a layer containing an aliphatic polyester and multiple layers containing a water-soluble polymer formed on the surface of the layer. According to Patent Document 2, this adhesion preventing material is capable of controlling the solubility of the surface when applied and wetted by the multiple water-soluble polymer layers, and is said to be able to easily maintain its shape even after being applied to an adherend.

[0005] International Publication No. WO 2011 / 081162 International Publication No. WO 2017 / 164264

[0006] Medical films with adjusted solubility immediately after application to an organ are known, as described in Patent Documents 1 and 2. However, medical films with a layer on the surface for controlling solubility, as described in these documents, tend to be thick, resulting in low absorbability in the body or high cost.

[0007] The present invention has been made in consideration of the above problems, and its object is to provide a medical film that can be easily repositioned even without providing a layer for controlling solubility.

[0008] One embodiment of the present invention for solving the above problems relates to medical films according to the following [1] to [7]. [1] A medical film comprising a crosslinked polymer material and a biodegradable resin, wherein the ratio q1 (V1 / V0) of the volume V1 after 10 seconds of immersion in a 0.2 M phosphate buffer solution (PB) with a pH of 6.0 to the volume V0 before immersion is 1.5 or less. [2] The medical film according to [1], wherein the ratio q2 (V2 / V0) of the volume V2 after 60 seconds of immersion in a 0.2 M phosphate buffer solution (PB) with a pH of 6.0 to the volume V0 before immersion is 1.9 or less. [3] The medical film according to [1] or [2], wherein the ratio q3 (V3 / V0) of the volume V3 after 900 seconds of immersion in a 0.2 M phosphate buffer solution (PB) with a pH of 6.0 to the volume V0 before immersion is 1.8 or more. [4] The medical film according to any one of [1] to [3], wherein the biodegradable resin is present in an amount of 5 to 95 parts by mass per 100 parts by mass of the crosslinked polymer material. [5] The medical film according to any one of [1] to [4], wherein the biodegradable resin is a polymer having glycolic acid as a structural unit, and the proportion of the polymer to the total mass of the biodegradable resin is 10 to 100% by mass. [6] The medical film according to any one of [1] to [5], wherein the thickness is 15 μm to 500 μm. [7] The medical film according to any one of [1] to [6], wherein the medical film is an adhesion barrier.

[0009] According to the present invention, a medical film is provided that can improve repositionability even without providing a layer for controlling solubility.

[0010] [Medical Film] One embodiment of the present invention relates to a medical film (hereinafter also simply referred to as "medical film") that contains a crosslinked polymer material and a biodegradable resin.

[0011] (Crosslinked Polymer Material) A crosslinked polymer material is a polymer material that swells when immersed in ultrapure water at 15 to 25°C. A crosslinked polymer material is a polymer material obtained by physically and / or chemically crosslinking the same or different types of polymer materials, and is typically a gel-like polymer material. The crosslinked polymer material is preferably composed of a polymer material that swells in water and then becomes soluble.

[0012] The crosslinked polymer material can be, for example, a crosslinked anionic polymer material. The anionic polymer material may be a polymer material having a repeating structure with anionic groups, or a polymer material obtained by chemically modifying a polymer compound with anionic substituents. The anionic polymer material may also be a polymer material having cationic substituents in addition to the anionic substituents. The anionic groups may be carboxyl groups, hydroxyl groups, sulfo groups, etc. The anionic groups may partially form salts with alkali metals such as sodium and potassium, or alkaline earth metals such as calcium and magnesium.

[0013] The polymer material may be a polysaccharide, a protein, or a synthetic polymer, of which polysaccharides and proteins are preferred.

[0014] Examples of saccharides that are anionic polymeric materials include natural saccharides such as pullulan, alginic acid, hyaluronic acid, chondroitinic acid, dextran acid, and pectin, as well as saccharides having anionic groups introduced by modification such as carboxymethyl amylose, carboxymethyl cellulose, carboxymethyl dextran, carboxymethyl starch, sulfated cellulose, and sulfated dextran. Of these, alginic acid, hyaluronic acid, carboxymethyl amylose, and carboxymethyl cellulose are preferred because of their ease of handling.

[0015] Examples of proteins that are anionic polymeric materials include gelatin, collagen, albumin, fibrin, and chemically modified versions of these. The protein may be a polymer of amino acids (polyamino acids) having anionic groups, such as polyglutamic acid and polyaspartic acid. Of these, acid-treated gelatin, which has carboxyl groups generated by hydrolysis of acid amides, is preferred.

[0016] The anionic polymer material can be identified by various instrumental analyses, acid titration, or a combination of these. For example, the anionic polymer material can be identified by a method using a spectroscopic instrument such as FT-IR, a method using deuterated dimethyl sulfoxide (deuterated DMSO) or the like to heat the polymer material to a level where it dissolves, followed by analyzing the resulting solution with NMR, or a method using an instrumental analyzer such as liquid chromatography as appropriate to heat the polymer material to a level where it dissolves, followed by analyzing the resulting solution with DMSO or the like.

[0017] The crosslinking of the polymeric material may be a physical crosslink formed by introducing a cationic substituent into a polyanionic polymeric material, or a chemical crosslink formed by reacting the polymeric materials together directly or via other molecules. The crosslinking of the polymeric material may be carried out by subjecting the polymeric material to a crosslinking treatment such as ultraviolet treatment, heat treatment, or crosslinking agent treatment. Of these, crosslinking agent treatment is preferred.

[0018] Examples of crosslinking agents used in the crosslinking treatment include ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, and N,cyclohexyl-N'-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonic acid. Treatment with these crosslinking agents can introduce cationic groups into the polyanionic polymer material. Furthermore, intermolecular interactions between the anionic groups of one molecule and the cationic groups of another molecule can physically crosslink the molecules of the polymer material. Of these, EDC is preferred due to its ease of handling.

[0019] Crosslinking with a crosslinking agent can be carried out by dissolving the polymer material in water or an aqueous medium, adding the crosslinking agent, and stirring. The state of the water or aqueous solution may be adjusted depending on the type of crosslinking agent. For example, when EDC is used as the crosslinking agent, it is preferable to add an acid such as 0.01 M hydrochloric acid appropriately to maintain a low pH (e.g., pH 4.0 to 5.5) during the reaction to dissociate the anionic groups of the polyanionic polymer.

[0020] The amount of crosslinking agent is preferably 0.5 eq. or more and 10 eq. or less relative to the reactive functional groups of the polymer material (e.g., hyaluronic acid), more preferably 1 eq. or more and 6 eq. or less, and even more preferably 2 eq. or more and 5 eq. or less. As will be described later, by increasing the amount of crosslinking agent, the initial swelling degree of the medical film can be reduced.

[0021] In addition, crosslinking may be performed between different polymer materials. The crosslinking may be chemical crosslinking, which can generate chemical bonds by chemically reacting these polymer materials with each other, or physical crosslinking, which can be performed by enhancing intermolecular interaction with a crosslinking agent. For example, from the viewpoint of safety, a crosslinked combination of hyaluronic acid and carboxymethyl cellulose can be used as the crosslinked polymer material.

[0022] (Biodegradable Resin) A biodegradable resin is a resin that is decomposed in vivo. The biodegradable resin can be a biodegradable polyester. Examples of biodegradable polyesters include biodegradable aliphatic polyesters, specifically polyglycolic acid, polylactic acid, polycaprolactone, polydioxanone, and copolymers thereof. Among these, glycolic acid (co)polymers, such as glycolic acid homopolymers and copolymers containing a structure derived from glycolic acid, are preferred because of their fast decomposition rate in vivo.

[0023] The (co)polymer of glycolic acid may be a homopolymer of glycolic acid or a copolymer of glycolic acid and another monomer. The copolymer may be a copolymer of glycolic acid with a hydroxycarboxylic acid such as lactic acid, hydroxypropionic acid, hydroxybutyric acid, hydroxyvaleric acid, hydroxycaproic acid, or hydroxybenzoic acid, or a lactone such as caprolactone, or a water-soluble polymer whose biological safety has been confirmed, such as polyethylene glycol. From the viewpoint of reducing the initial swelling degree, the proportion of structural units derived from glycolic acid in the biodegradable resin is preferably 5% by mass or more and 100% by mass or less, more preferably 20% by mass or more and 99% by mass or less, and even more preferably 40% by mass or more and 95% by mass or less.

[0024] The type of biodegradable resin can be identified, for example, using NMR. When the biodegradable resin is a resin that does not dissolve in a solvent at room temperature, such as a glycolic acid polymer, a measurement sample can be prepared by dissolving the resin in deuterated dehydrogenated DMSO by heating. Alternatively, other analytical devices such as FT-IR or GC-MS may be used in combination.

[0025] These biodegradable resins slowly release acid through hydrolysis when the medical film is applied to an organ and comes into contact with water. This slowly released acid reduces the swelling of the medical film at the initial stage of application, reducing its adhesion to the organ and improving the repositionability of the medical film. Furthermore, the slowly released acid delays the decomposition of the crosslinked polymer material, which is thought to maintain the strength of the medical film and improve the repositionability of the medical film.

[0026] The number-average molecular weight of the biodegradable resin is preferably 1,000 to 150,000, more preferably 5,000 to 100,000, and even more preferably 10,000 to 50,000. The weight-average molecular weight of the biodegradable resin is preferably 2,000 to 300,000, more preferably 10,000 to 200,000, and even more preferably 20,000 to 100,000. By reducing the number-average molecular weight and weight-average molecular weight, the acid-releasing capacity can be increased, maintaining the adhesion and film strength of the medical film after application. Furthermore, when the biodegradable resin is particulate, reducing the number-average molecular weight and weight-average molecular weight makes the biodegradable resin more easily pulverized, resulting in particles with smaller particle sizes. As described below, the smaller the particle size, the greater the effect of reducing the adhesion of the medical film to organs during the initial application period.

[0027] The number-average molecular weight and mass-average molecular weight of the biodegradable resin refer to values ​​obtained by separating the biodegradable resin from the medical film. The number-average molecular weight is a value measured in accordance with ISO 16014-1:2012. Specifically, the biodegradable resin was subjected to gel permeation chromatography (GPC) (manufactured by Resonac, shodex GPC-104, detector: RI, column: HFIP-606M x 2) with CF4 as the solvent to a concentration of 5 mM. 3 Measurement is carried out using a solution of COONa dissolved in hexafluoropropanol (HFIP) and polymethyl methacrylate (PMMA) as a standard substance.

[0028] The biodegradable resin may be in the form of particles or fibers. When in the form of fibers, the biodegradable resin may be a monofilament or a multifilament, and may be in the form of a nonwoven fabric, a woven fabric, a knitted fabric, a braided fabric, or the like.

[0029] When the biodegradable resin is particulate, the average particle size is not particularly limited, but is preferably 0.1 μm to 30 μm, more preferably 1 μm to 20 μm, and even more preferably 1 μm to 15 μm. The larger the average particle size, the easier it is to handle the biodegradable resin when preparing the film. The smaller the average particle size, the larger the particle surface area, resulting in a larger contact area with the crosslinked polymer material, and the higher the acid sustained release capacity, enhancing the effect of the biodegradable resin in reducing the adhesion of the medical film to organs during initial application. The average particle size of the biodegradable resin refers to the value in the medical film. It is observed at 100x magnification using a digital microscope (manufactured by Keyence Corporation) and a digital image is obtained. The image of the acquired measurement area is loaded into image analysis software MIPAR (manufactured by LightStone), and the circular diameter calculated from the area of ​​the biodegradable resin particle image is used as the diameter. “Smart Cluster” was set to “Fill Type: Class”, “Classes: 4~10”, “Edge Type: Dark to Bright”, “Edge Clean: 0~5”, and “Speed: 2”. “Basic Threshold” was set to “Value: 80~150”. “Reject Features” was set to “Measurement: Area”, “Target: Objects”, “Edges: Include”, and “Units: μm 2 ”, “Threshold Value: 100”, “Type: Reject Features < / =”

[0030] When it is a nonwoven fabric, the basis weight of the biodegradable resin is 1.2 g / m 2 100.0g / m or more 2 Preferably, the content is 3.4 g / m or less. 2 65.0g / m or more 2 More preferably, it is 5.0 g / m or less. 2 31.5g / m or more 2 It is more preferable that the weight per unit area is equal to or less than 10 ...

[0031] The content of the biodegradable resin is preferably 5 parts by weight or more and 95 parts by weight or less, more preferably 15 parts by weight or less and 85 parts by weight or less, and even more preferably 20 parts by weight or more and 70 parts by weight or less, when the content of the crosslinked polymer material is 100 parts by weight.

[0032] The content of biodegradable resin in a medical film can be calculated from the amount of biodegradable resin added during the production of the medical film, or by extracting the biodegradable resin from the medical film and measuring its mass. The mass of biodegradable resin extracted from a medical film can be measured, for example, by the following method: The medical film is treated with a room-temperature acid-containing solution to decompose the crosslinked polymer material and dissolve it in the solution. The resulting acid-containing solution is suction-filtered and washed with low-temperature water to remove the crosslinked polymer material, and the solids are further washed with acetone. The resulting solids are dried for 5 minutes in a vacuum dryer set at 40°C, and the weight of the resulting solids is measured.

[0033] (Other Components) The medical film may contain lubricants, emulsifiers, colorants, antioxidants, weathering agents, heat stabilizers, nucleating agents, ultraviolet absorbers, colorants, antibacterial agents, etc. The content of these components is preferably 0% by mass or more and 20% by mass or less, more preferably 0% by mass or more and 10% by mass or less, and even more preferably 0% by mass or more and 5% by mass or less, relative to the total mass of the medical film.

[0034] (Swellability of medical film) Medical films have low initial swelling when contacted with water. Specifically, the ratio q1 (V1 / V0) (swelling degree) of the volume V1 after 10 seconds of immersion in a phosphate buffer solution (PB) with a pH of 6.0 and a concentration of 0.2 M to the volume V0 before immersion is 1.5 or less. Furthermore, it is preferable that the ratio q2 (V2 / V0) of the volume V2 after 60 seconds of immersion in the phosphate buffer solution (PB) to the volume V0 before immersion is 1.9 or less. The amount of phosphate buffer solution used here must be an amount that completely immerses the medical film. For example, when 1 cm of medical film is immersed in a 10 mL vial, 3The swelling property is evaluated by completely immersing the sample in 5 mL of phosphate buffer.

[0035] For example, Seprafilm, a commercially available adhesion barrier (medical film), has a ratio q1 (V1 / V0) of its volume V1 after 10 seconds of immersion in phosphate buffer (PB) to its volume V0 before immersion, of approximately 1.7. Medical films with high initial water absorption and a tendency to swell tend to adhere well to organs from the beginning of application and tend to lose strength immediately after application. Therefore, medical films applied to organs are difficult to remove, and forcible removal often results in the film losing its shape and becoming impossible to reapply.

[0036] In contrast, if the initial water absorbency of the medical film is reduced to make it less likely to swell, the initial adhesion to the organ after application can be reduced, making it easier to remove from the organ, and it is also less likely to lose its shape when removed from the organ. Furthermore, even if the medical film curls when removed from the organ, it can easily uncurl. Therefore, such a medical film can be easily reapplied to the organ.

[0037] For example, when using a medical film during abdominal surgery, it is expected that the film will be peeled off and reapplied within a few tens of seconds of being applied to an unintended location on the surface of an organ. Therefore, a medical film with a low degree of swelling after immersion for 10 or 30 seconds is particularly suitable for use in abdominal surgery. From this perspective, the ratio q1 (V1 / V0) of the volume V1 after 10 seconds of immersion in the phosphate buffer (PB) to the volume V0 before immersion is preferably 1.5 or less, more preferably 1.3 or less, and even more preferably 1.2 or less. Furthermore, the ratio q4 (V4 / V0) of the volume V4 after 30 seconds of immersion in the phosphate buffer (PB) to the volume V0 before immersion is preferably 1.6 or less, more preferably 1.5 or less, and even more preferably 1.3 or less. The lower limits of the volume ratios q1 and q4 are not particularly limited, but can be 1.0 or greater.

[0038] Furthermore, when using a medical film during laparoscopic surgery, the field of view is more limited than in open surgery, and the film must be manipulated using forceps, etc., which means that it is expected to take longer to reapply than in open surgery. Therefore, medical films with a low degree of swelling after 60 seconds of immersion are particularly suitable for laparoscopic surgery. From this perspective, the ratio q2 (V2 / V0) of the volume V2 after 60 seconds of immersion in the phosphate buffer (PB) to the volume V0 before immersion is preferably 1.9 or less, more preferably 1.7 or less, and even more preferably 1.5 or less. Furthermore, the ratio q5 (V5 / V0) of the volume V5 after 90 seconds of immersion in the phosphate buffer (PB) to the volume V0 before immersion is preferably 1.6 or less, more preferably 1.5 or less, and even more preferably 1.3 or less. The lower limits of the volume ratios q2 and q5 are not particularly limited, but can be 1.0 or greater. Furthermore, when a film that has been applied once is peeled off and reapplied, the film may curl up. Even when the film is being unfolded, it is in contact with water, which creates an environment in which swelling progresses, but when the volume ratios q2 and q5 are in the above-mentioned preferred ranges, the film becomes easy to unfold.

[0039] On the other hand, from the viewpoint of preventing misalignment of the medical film due to organ deformation or the like after application in the correct position, it is preferable that the medical film swell sufficiently after a predetermined time has elapsed since application. From this viewpoint, the ratio q6 (V6 / V0) of the volume V6 after 300 seconds of immersion in the phosphate buffer (PB) to the volume V0 before immersion is preferably 1.6 or more, more preferably 1.8 or more. Furthermore, the ratio q3 (V3 / V0) of the volume V3 after 900 seconds of immersion in the phosphate buffer (PB) to the volume V0 before immersion is preferably 1.8 or more, more preferably 1.9 or more, and even more preferably 2.0 or more. The upper limit of the degree of swelling during these periods is not particularly limited, but can be 6.5 or less.

[0040] Furthermore, even if the pH changes, the degree of swelling of the medical film when immersed for 900 seconds remains the same, and there is no problem with attaching it to a living body.

[0041] The volumes V1 to V6 can be determined by the following method.

[0042] One side of the film is the x-axis, the other side perpendicular to the x-axis is the y-axis, and the direction perpendicular to the plane consisting of the x-axis and y-axis is the z-axis. When the medical film is thin, it is difficult to measure the thickness after immersion. Therefore, the volume of the medical film in this specification is calculated assuming that the rate of increase in each of the x-axis, y-axis, and z-axis directions is the same. Specifically, the volume V0 before immersion is determined by placing the medical film and a ruler on a blue writing pad so that the lengths of the medical film's sides can be seen, and photographing the sample so that the outline can be seen. The lengths of the four sides of the medical film on the same surface measured from the obtained image are a1, a2, a3, and a4, and the average length of the four sides is l. 0 and calculate the volume before immersion V0 using Equation 1.

[0043]

[0044] Similarly, to determine the volume (V1 to V6) after immersion in phosphate buffer solution, the medical film and a ruler are placed on a blue writing pad so that the lengths of the medical film's sides can be seen, and a photograph is taken so that the outline of the sample can be seen. The four sides of the same surface as the surface measured at V0, measured from the resulting image, are designated b1, b2, b3, and b4. The average length of the four sides, l1, is calculated, and the volume after immersion is calculated using Equation 2. Note that Equation 2 shows how to calculate the volume V1 after 10 seconds of immersion, but volumes V2 to V6 can also be calculated in a similar manner.

[0045]

[0046] The volume ratios q1 to q6 calculated from these volumes V0 to V6 are the average values ​​of three measurements taken using a medical film manufactured with the same formulation. Even when the medical film is not approximately rectangular in plan view, the volume ratios q1 to q6 can be calculated by assuming that the rate of increase in each direction in plan view is the same as the rate of increase in the thickness direction.

[0047] (Other Properties of Medical Films) Medical films also have high initial strength immediately after wetting. Specifically, a sample cut into a strip with a long side of 40 mm and a short side of 10 mm is fixed to a chuck with a chuck distance of 20 mm. The central 10 mm x 10 mm area on one side of the sample is contacted with ultrapure water for 10 seconds, and then pulled to both sides at 0.1 mm / sec. The maximum tensile strength can be 1.50 MPa or more, preferably 2.00 MPa or more, and more preferably 6.00 MPa or more. The upper limit of the maximum tensile strength is not particularly limited, but can be 300.00 MPa or less.

[0048] Furthermore, the medical film has a high adhesive strength to organs. Specifically, a sample was cut into strips with a long side of 50 mm and a short side of 10 mm, and mending tape (product number 810-1-18, manufactured by 3M Japan, base material: acetate film, adhesive: acrylic) was attached to the side opposite to the side that would come into contact with a simulated organ (silicone rubber sheet (thickness: 3 mm), product number 6-611-05, manufactured by AS ONE Corporation). Using a creep meter (RE2-33005B, manufactured by Yamaden Co., Ltd.), the short side of the sample was fixed to a tensile chuck at 5 mm and the simulated organ was fixed to the other tensile chuck. The long side of the sample, 40 mm and the short side of the sample, 10 mm, were then attached to the simulated organ wetted with ultrapure water for 900 seconds, and the adhesive strength when stretched at 0.05 mm / sec was greater than 0.05 N, and more preferably greater than 1.60 N. Such adhesive strength makes it possible to prevent the medical film from shifting in position due to deformation of the organ or the like after it has been attached to the correct position.

[0049] The swelling property of the medical film can be adjusted by the thickness of the medical film, the crosslinking state of the crosslinked polymer material, and the dispersibility of the biodegradable resin (if it is in particulate form).

[0050] For example, the thicker the medical film, the lower the initial swelling degree. The thickness of the medical film is preferably 15 μm or more and 500 μm or less, and more preferably 40 μm or more and 200 μm or less. Furthermore, from the viewpoint of achieving both a low initial swelling degree and a comfortable feel, the thickness of the composite layer is even more preferably 50 μm or more and 150 μm or less.

[0051] The crosslinking state of the crosslinked polymer material and the dispersibility of the biodegradable resin can be changed by appropriately adjusting the manufacturing conditions of the medical film.

[0052] (Uses) The medical film can be attached to organs, etc., and after a certain period of time, it begins to change shape (disintegrate) through decomposition and is ultimately absorbed into the body. The period from application until the change in shape occurs can be adjusted between 3 and 14 days. Furthermore, the period from application until the medical film is absorbed into the body and becomes invisible can be adjusted between 14 and 28 days. These periods can be adjusted depending on the type of crosslinked polymer material and the type of biodegradable resin.

[0053] Due to the above-mentioned properties, medical films can be used as dressings for affected areas to cover surgical wounds to prevent adhesions (anti-adhesion materials) or to prevent the development of ulcers or perforations. Medical films can also be used as sustained-release substrates for drugs or substrates for tissue regeneration. Alternatively, medical films can be applied to the wall surfaces of lumens in the body and used as gap-maintaining materials to maintain gaps.

[0054] [Method for Producing Medical Film] Medical films can be produced by crosslinking a polymeric material, compounding it with a biodegradable resin, and forming the resulting film.

[0055] Crosslinking of polymeric materials may be carried out by a method appropriate for the polymeric material, such as ultraviolet treatment, heat treatment, or crosslinking agent treatment. For example, crosslinking with EDC can be carried out by adding EDC to a solution of the polymeric material dissolved in water or an aqueous medium while stirring. In this case, it is preferable to add an acid such as HCl to make the solution acidic (e.g., pH 4.0 to 5.5). After crosslinking with a crosslinking agent, it is preferable to remove unnecessary substances by dialysis or the like.

[0056] The composite with the biodegradable resin may be carried out by a method appropriate for the shape and type of the biodegradable resin. For example, when the biodegradable resin is in the form of particles, monofilaments, or multifilaments, the biodegradable resin in these shapes may be added to a solution or dispersion containing the crosslinked polymer material and stirred. When the biodegradable resin is in the form of a nonwoven fabric, woven fabric, knitted fabric, or braided fabric, the biodegradable resin and the crosslinked polymer material may be composited within a frame into which the solution or dispersion is cast during film formation.

[0057] The film can be formed by drying the composite of the crosslinked polymer material and the biodegradable resin in a frame. Drying can be carried out by air drying at room temperature, freeze-drying, or by removing the solvent by heating. Alternatively, heat pressing (heating and pressure) can be carried out. These drying methods can also be combined.

[0058] At this time, the initial swelling degree of the medical film can be adjusted by adjusting the manufacturing conditions to adjust the crosslinking state of the crosslinked polymer material and the dispersibility of the biodegradable resin.

[0059] For example, increasing the stirring speed when crosslinking a polymeric material increases the frequency of contact between reacting molecules, further promoting the reaction and increasing the degree of crosslinking, thereby reducing the initial swelling of the medical film. On the other hand, a moderate stirring speed is preferred to prevent an increase in the initial swelling of the composite layer due to the application of strong shear forces to the crosslinked polymer gel, which can cause the rate of molecular cleavage to exceed the rate of crosslink formation by the reaction, or the generation of bubbles, which reduces the reaction efficiency and reduces the degree of crosslinking. To achieve a balance between these factors, the stirring speed is preferably 50 rpm or more and less than 750 rpm, and more preferably 150 rpm or more and less than 700 rpm.

[0060] Furthermore, the lower the temperature of the solution used to crosslink the polymer, the lower the initial swelling of the medical film. By carrying out the reaction at a low temperature, it is possible to generate an appropriate number of crosslinking points, resulting in a medical film with a low initial swelling due to a moderately high degree of crosslinking, but one that increases in swelling over time due to a degree of crosslinking that is not too high. On the other hand, if the solution temperature is too low, the reaction may take a long time or the reaction may not proceed. Therefore, in order to allow the reaction to proceed sufficiently in a short time and generate an appropriate number of crosslinking points, the crosslinking reaction temperature of the polymer is preferably between 0°C and 60°C, and more preferably between 0°C and 50°C.

[0061] By appropriately changing these production conditions, the initial swelling degree of the composite layer can be adjusted to fall within the above range.

[0062] [Other Embodiments] It goes without saying that the above-described embodiments are exemplary embodiments of the present invention, and the present invention may include embodiments other than the above-described embodiments within the scope of its core technical concept.

[0063] The present invention will be described in detail based on examples, but the present invention is not limited to these examples.

[0064] The weight-average molecular weights listed below are the published values ​​of the manufacturers when the manufacturer's name is listed, and when not otherwise specified, are values ​​measured using 5 mM CF as the solvent.3 The values ​​were measured by gel permeation chromatography (GPC) of COONa using hexafluoropropanol (HFIP) as a solvent, and calculated using polymethyl methacrylate (PMMA) as a standard substance. Although similar results were obtained using either instrument, in this example, a Shodex GPC-104 (detector: RI, column: HFIP-606M x 2) manufactured by Resonac Corporation was used.

[0065] [Experiment 1] In Experiment 1, the relationship between the initial swelling degree of the medical film and the ease of re-application, ease of spreading after peeling, tensile strength, and adhesive strength was investigated.

[0066] 1. Preparation of Medical Films 1-1. Preparation of Crosslinked Polymer Materials 1-1-1. Preparation of HA / CMC Condensate-1 1,650 mg of hyaluronic acid (HA) (Kewpie Corporation, molecular weight 2.2-2.5 million) and 750 mg of carboxymethyl cellulose (CMC) (Tokyo Chemical Industry Co., Ltd., molecular weight 250,000, degree of etherification 0.5-0.8) were weighed. HA was added to a beaker containing 300 mL of ultrapure water and dissolved, followed by the addition of CMC to obtain a mixed solution. Then, 0.1 N HCl was added to adjust the pH of the contents to 4.50-5.20 to obtain a HA / CMC solution. 3,180 mg of ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (Dojindo Laboratories) was weighed and dissolved in 7.5 mL of ultrapure water to obtain an EDC solution. While stirring the HA / CMC solution at 25°C and a stirring speed of 600 rpm, an appropriate amount of 0.1 N HCl was added to adjust the pH to 4.70 to 5.10, and the entire amount of the EDC solution was then added. After addition, the solution was stirred for approximately 120 minutes until the pH no longer fluctuated, yielding a reaction solution. Finally, the stirred reaction solution was placed in a dialysis membrane with a molecular weight cutoff of 12,000 to 14,000, and stirred in ultrapure water. The dialysate (ultrapure water) was completely replaced three times over a 36-hour period from the start of dialysis, yielding HA / CMC condensate-1 (crosslinked polymer material) (condensate 1).

[0067] 1-1-2. Preparation of HA / CMC Condensate-2 4,400 mg of hyaluronic acid (HA) (Kewpie Corporation, molecular weight 2.2 million) and 2,000 mg of carboxymethyl cellulose (CMC) (Tokyo Chemical Industry Co., Ltd., molecular weight 1,500,000, degree of etherification 0.5-0.8) were weighed out. HA was added to a beaker containing 800 mL of ultrapure water and dissolved, followed by the addition of CMC to obtain a HA / CMC solution. 8,500 mg of ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (Dojindo Laboratories) was weighed out and dissolved in 20.0 mL of ultrapure water to obtain an EDC solution. While stirring the HA / CMC solution at 800 rpm at 80 °C, the entire EDC solution was added while adjusting the pH to 4.50-5.20 by adding 0.1 N HCl. After addition, the mixture was stirred for approximately 120 minutes until the pH no longer fluctuated, yielding a reaction solution. Finally, the reaction solution after stirring was placed in a dialysis membrane with a molecular weight cutoff of 12,000 to 14,000, and stirred in ultrapure water. The dialysis solution (ultrapure water) was exchanged three times over a 36-hour period from the start of dialysis, yielding HA / CMC condensate-2 (condensate 2).

[0068] 1-1-3. Preparation of HA / CMC condensate-3 HA / CMC condensate-3 (condensate 3) was obtained in the same manner as in the preparation of HA / CMC condensate-1, except that the EDC solution was added while stirring the HA / CMC solution at a stirring speed of 200 rpm.

[0069] 1-1-4. Preparation of HA / CMC condensate-4 HA / CMC condensate-4 (condensate 4) was obtained in the same manner as in the preparation of HA / CMC condensate-1, except that the EDC solution was added while stirring the HA / CMC solution at a stirring speed of 800 rpm.

[0070] 1-1-5. Preparation of HA / CMC Condensate-5 HA / CMC Condensate-5 (Condensate 5) was obtained in the same manner as in the preparation of HA / CMC Condensate-1, except that the EDC solution was added while stirring the HA / CMC solution at 60°C.

[0071] 1-1-6. Preparation of HA / CMC condensate-6 HA / CMC condensate-6 (condensate 6) was obtained in the same manner as in the preparation of HA / CMC condensate-1, except that the EDC solution was added while stirring the HA / CMC solution at 40°C.

[0072] The concentration of Condensate 1 to Condensate 6 ((mass of HA and CMC used as materials) / (mass of HA, CMC, and water used in the reaction)) was all 0.77 wt %.

[0073] 1-2. Preparation of medical film The biodegradable resins shown in Table 1 were prepared. All of the powdered materials were passed through a sieve with a mesh size of 38 μm, and the nonwoven fabric materials were used with a basis weight of 10.5 g / m. 2 The following items were used.

[0074]

[0075] 1-2-1. Preparation of Film 1 100 g of HA / CMC condensate-1 was weighed out and added to a beaker. 210.5 mg of resin 3 was weighed out and added to the HA / CMC condensate-1 in the beaker, followed by stirring. An 11 x 11 cm frame was prepared on a glass plate, and condensate 1 to which PGA powder had been added was poured into the frame. This was dried at a temperature of 30°C for approximately 3 days. After drying, the film was heat-treated using a heat press at 90°C for 15 minutes, and then at 120°C for 10 minutes, to obtain Film 1.

[0076] 1-2-2. Preparation of Film 2 Film 2 was obtained in the same manner as in the preparation of Film 1, except that Resin 3 was replaced with Resin 2.

[0077] 1-2-3. Preparation of Film 3 100 g of condensate 1 was weighed and added to a beaker. The contents of the beaker were stirred. An 11 x 11 cm frame was prepared on a glass plate, and 50 g of condensate 1 was poured into the frame. Three sheets (approximately 210.0 mg) of resin 4, a nonwoven fabric cut to 11 x 11 cm, were stacked on top of each other and placed tightly within the frame to cover the condensate 1. After confirming that the PGA nonwoven fabric had absorbed the HA / CMC condensate-1, the remaining 50 g of HA / CMC condensate-1 was poured into the frame. The film was dried at a temperature of 30°C for approximately 3 days. After drying, the film was heat-treated using a heat press at 90°C for 15 minutes, and then at 120°C for 10 minutes, to obtain Film 3.

[0078] 1-2-4. Preparation of Film 4 Film 4 was obtained in the same manner as in the preparation of Film 1, except that Resin 3 was replaced with Resin 5.

[0079] 1-2-5. Preparation of Film 5 Film 5 was obtained in the same manner as in the preparation of Film 1, except that Resin 3 was replaced with Resin 6.

[0080] 1-2-6. Preparation of Film 6 Film 6 was obtained in the same manner as in the preparation of Film 1, except that Resin 3 was replaced with Resin 1.

[0081] 1-2-7. Preparation of Film 7 Film 7 was obtained in the same manner as in the preparation of Film 1, except that Condensate 1 was replaced with Condensate 3.

[0082] 1-2-8. Preparation of Film 8 Film 8 was obtained in the same manner as in the preparation of Film 1, except that Condensate 1 was replaced with Condensate 6.

[0083] 1-2-9. Preparation of Film 9 Film 9 was obtained in the same manner as in the preparation of Film 1, except that the amount of Resin 3 added was 701.7 mg.

[0084] 1-2-10. Preparation of Film 10 Film 10 was obtained in the same manner as in the preparation of Film 1, except that the amount of Resin 3 added was 70.2 mg.

[0085] 1-2-11. Preparation of Film 11 Film 11 was obtained in the same manner as in the preparation of Film 1, except that the amount of Resin 3 added was 140.3 mg.

[0086] 1-2-12. Preparation of Film 12 A commercially available medical film (Seprafilm, manufactured by Baxter; "Seprafilm" is a registered trademark of Baxter International) was used as film 12.

[0087] 1-2-13. Preparation of Film 13 Film 13 was obtained in the same manner as in the preparation of Film 1, except that no biodegradable resin was added.

[0088] 1-2-14. Preparation of Film 14 Film 14 was obtained in the same manner as in the preparation of Film 1, except that Resin 3 was replaced with Resin 7.

[0089] 1-2-15. Preparation of Film 15 90 g of Condensate 2 was weighed and added to a beaker. 252.0 mg of Resin 8 was weighed and added to the beaker, and the contents of the beaker were stirred. An 11 x 11 cm frame was made on a glass plate using silicone rubber, and Condensate 2 to which PGA powder had been added was poured into the frame. After air drying at room temperature, the film was heat-treated using a heat press at 90°C for 15 minutes and then at 120°C for 10 minutes to obtain Film 15.

[0090] 1-2-16. Preparation of Film 16 Film 16 was obtained in the same manner as in the preparation of Film 15, except that no biodegradable resin was added.

[0091] 1-2-17. Preparation of Film 17 Film 17 was obtained in the same manner as in the preparation of Film 1, except that Condensate 4 was used.

[0092] 1-2-18. Preparation of Film 18 Film 18 was obtained in the same manner as in the preparation of Film 1, except that Condensate 5 was used.

[0093] Table 2 shows the type, concentration, and amount of HA / CMC condensate used to prepare each sample, the type and amount of biodegradable resin used, and the parts by weight of biodegradable resin per 100 parts by mass of HA / CMC.

[0094]

[0095] 2. Evaluation 2-1. Swelling Degree Each of Films 1 to 18 was cut into a 1 cm x 1 cm piece using a rotary cutter to prepare a sample.

[0096] 6.24 g of sodium dihydrogen phosphate dihydrate and 14.33 g of disodium hydrogen phosphate dodecahydrate were each dissolved in 0.2 L of ultrapure water to prepare a 0.2 M solution. Then, these solutions were mixed to prepare a PB solution with a pH of 6.0.

[0097] Each sample was placed on a blue writing pad with a ruler and photographed so that the outline of the sample could be seen.

[0098] 5 mL of the prepared PB solution was added to a 10 mL vial, and each sample was immersed in the PB solution for 10 seconds. The sample was then removed and placed on a blue writing pad with a ruler, and the sample's outline was photographed. After the photograph, the sample was returned to the PB solution and immersed for 30 seconds. The sample was then removed and placed on a blue writing pad with a ruler, and the sample's outline was photographed. After immersion for 60 seconds, the sample was removed and placed on a blue writing pad with a ruler, and the sample's outline was photographed. After immersion for 300 seconds, the sample was removed and placed on a blue writing pad with a ruler, and the sample's outline was photographed. After immersion for 900 seconds, the sample was removed and placed on a blue writing pad with a ruler, and the sample's outline was photographed.

[0099] The lengths of the four sides of each sample were determined from the photographed images. The average length of the four sides of the sample before immersion in the PB solution was determined as l 0 The average length of the four sides after each immersion time is l 1 Then, the ratio of these (l 1 3 / l 0 3 ) was calculated and used as the degree of swelling after each immersion time.

[0100] The swelling degree of each sample is shown in Table 1.

[0101]

[0102] [Discussion] Table 3 shows that all of Films 1 to 11 are films that have a suppressed initial swelling degree, but have a high swelling degree after a predetermined time has elapsed.

[0103] 2-2-1. Ease of Reapplication Films 1 to 18 were applied to simulated organs (Kotobuki Medical Co., Ltd., VTT-STANDARD-TYPE, VTT-STD) that were thoroughly moistened with ultrapure water. After wiping off the surface moisture with a Kimtowel, 1 x 2 cm pieces of Films 1 to 18 were placed on the simulated organ and left to stand for 30 seconds. After that, the films were peeled off from the simulated organ and reapplied to adjacent areas of the same simulated organ. Five panelists evaluated the ease of reapplication on a 9-point scale, with 1 being difficult to reapplication and 9 being easy to reapplication. The average of the panelists' ratings was taken as the ease of reapplication for each film.

[0104] 2-2-2. Ease of spreading after peeling A simulated organ (Kotobuki Medical Co., Ltd., VTT-STANDARD-TYPE, VTT-STD) was thoroughly moistened with ultrapure water, the surface moisture was wiped off with a Kimtowel, and then 200 μL of ultrapure water was poured over the entire surface of the simulated organ. Films 1 to 18, each measuring 1 x 3 cm, were placed on the simulated organ and left to stand for 30 seconds, after which they were peeled off from the simulated organ and reapplied to an adjacent area of ​​the same simulated organ. Five monitors evaluated the condition of the films when reapplied. The average of the monitors' evaluations was taken as the ease of spreading each film after peeling. The evaluation criteria are as follows, with a rating of 4 or higher being considered easy to reapply. 1: Cannot be spread, tears 2: Takes more than 90 seconds to spread 3: Can be spread within 30 to 90 seconds 4: Entire film curls up but can be spread within 30 seconds 5: Partially curled up but can be spread

[0105] The evaluation results of the ease of re-adhesion and the ease of spreading after peeling are shown in Table 4.

[0106]

[0107] [Discussion] Table 4 shows that films 1 to 11 have a small initial swelling degree, are easily repositionable, and are easily unfolded after being applied and removed. According to the inventors' findings, the swelling degree of a film when water is poured onto one side and allowed to stand for 30 seconds is considered to be equivalent to the swelling degree of the film when the entire film is immersed in a PB solution for 10 seconds. Therefore, Tables 3 and 4 show that medical films with a low swelling degree when immersed in a PB solution for 10 seconds have high repositionability.

[0108] 2-3. Tensile Strength Films 1, 5-6, and 9-13 (Film 12 was Seprafilm (manufactured by Baxter)) were cut into strips with long sides of 40 mm and short sides of 10 mm to prepare samples. Using a creep meter (manufactured by Yamaden Co., Ltd., RE2-33005B), the tensile strength of the samples wetted with ultrapure water was measured. The samples were fixed to the chucks so that the distance between the chucks was 20 mm, and a piece of Bellclean (manufactured by Ion Co., Ltd., product number E-2) soaked in ultrapure water was placed in close contact with a 10 mm x 10 mm central area on one side of the sample and left for 10 seconds. After 10 seconds, the sample was pulled at 0.1 mm / sec, and the tensile strength (MPa) was measured.

[0109] The measurement results of the tensile strength of each sample are shown in Table 5.

[0110]

[0111] [Discussion] Table 5 shows that medical films with a low initial swelling degree are less likely to lose strength when applied to organs and are easier to peel off and reapply. The cross-linked polymeric materials that make up medical films swell and gel when they absorb water. Strength decreases as the film transforms into a gel, but this is thought to be due to the low initial swelling degree, which slows the loss of strength in the medical films. Furthermore, films 5 and 6 use resins 6 and 1, which have low molecular weights, resulting in a greater amount of sustained acid release, which slows the loss of strength in the medical films and likely explains their high tensile strength.

[0112] 2-4. Adhesion Strength Films 1, 5, 6, 12 (Seprafilm (Baxter)), and 13 were cut into strips measuring 50 mm long and 10 mm short to prepare samples. Surface adhesion strength to a simulated organ (a silicone rubber sheet (3 mm thick) manufactured by AS ONE Corporation, product number 6-611-05) wetted with ultrapure water was measured using a creep meter (Yamaden, product number RE2-33005B). At this time, mending tape (3M Japan, product number 810-1-18, base material: acetate film, adhesive: acrylic) was attached to the surface of each sample opposite the surface that would come into contact with the simulated organ. The short side of the measurement sample was fixed 5 mm long to one tensile chuck, and the simulated organ was fixed to the other tensile chuck. The sample's long side (40 mm long) and short side (10 mm short) were placed in close contact with the wetted simulated organ and left for 900 seconds. After 900 seconds, the adhesive strength (N) was measured by pulling at 0.05 mm / sec. As comparative examples, measurements were also made on commercially available synthetic adhesion barriers, Interceed (manufactured by Johnson & Johnson) and Tenaleaf (manufactured by Gunze).

[0113] The results of measuring the adhesive strength of each sample are shown in Table 6.

[0114]

[0115] [Discussion] Table 6 shows that Films 1, 5, and 6 exhibited high adhesion strength, but differences in adhesion strength occurred among the films. This is thought to be due to the glycolic acid component contained in the glycolic acid (co)polymer releasing acid upon contact with water, which inhibits the decomposition of the crosslinked polymer material. Film 6 has a smaller molecular weight of the glycolic acid (co)polymer than Film 1 and a higher amount of glycolic acid in the glycolic acid (co)polymer than Film 5, resulting in a greater amount of acid release. As a result, decomposition of the crosslinked polymer material was inhibited. Therefore, Film 6 exhibited higher adhesion strength than Film 1, which showed the same degree of swelling after 900 seconds, and Film 6 also exhibited higher adhesion strength despite its lower degree of swelling than Film 5.

[0116] [Experiment 2] In Experiment 2, Film 1, Film 6, and films of these with different thicknesses were used to examine the relationship between the thickness of the medical film and the degree of swelling.

[0117] 1. Preparation of Medical Films 1-1. Film 1-2 53 g of condensate 1 was weighed out and added to a beaker. 111.6 mg of resin 3 was weighed out and added to the beaker, followed by stirring. An 11 x 11 cm frame was prepared on a glass plate, and condensate 1 with resin 3 added was poured into the frame. The film was dried at a temperature of 30°C for approximately 3 days. After drying, the film was heat-treated using a heat press at 90°C for 15 minutes, and then at 120°C for 10 minutes, to obtain film 1-2.

[0118] 90 g of Condensate 1 was weighed and added to a beaker. 189.5 mg of Resin 3 was weighed and added to the beaker, and film 1-3 was obtained in the same manner as film 1-2.

[0119] 200 g of Condensate 1 was weighed out and added to a beaker. 421 mg of Resin 3 was weighed out and added to the beaker, and film 1-3 was obtained in the same manner as film 1-2.

[0120] 50 g of the condensate 1 was weighed and added to a beaker. Film 6-2 was obtained in the same manner as in the production of film 1-2, except that resin 3 was not added.

[0121] 75 g of the condensate 1 was weighed and added to a beaker. Film 6-3 was obtained in the same manner as in the production of film 1-2, except that resin 3 was not added.

[0122] 2. Measurements Using the same procedures as in Experiment 1, the swelling degrees of Film 1, Films 1-2 to 1-4, Film 13, Film 13-2 and Film 13-3 were measured.

[0123] The measurement results of the swelling degree of each sample are shown in Table 7.

[0124]

[0125] As shown in Table 7, the greater the thickness, the lower the initial swelling degree of the medical film.

[0126] This application claims priority from Japanese Patent Application No. 2023-077267, filed May 9, 2023. The entire disclosure and claims of that application as originally filed are incorporated herein by reference.

[0127] The medical film according to the present invention has good re-adhesion properties to the affected area.

Claims

1. A medical film comprising a crosslinked polymer material and a biodegradable resin, wherein the ratio q1 (V1 / V0) of the volume V1 after immersion in a phosphate buffer solution (PB) having a pH of 6.0 and a concentration of 0.2 M to the volume V0 before immersion is 1.5 or less.

2. The medical film according to claim 1, wherein the ratio q2 (V2 / V0) of the volume V2 after immersion for 60 seconds in a phosphate buffer solution (PB) with a pH of 6.0 and a concentration of 0.2 M to the volume V0 before immersion is 1.9 or less.

3. The medical film according to claim 1 or 2, wherein the ratio q3 (V3 / V0) of the volume V3 after immersion in a phosphate buffer solution (PB) of pH 6.0 and concentration 0.2 M to the volume V0 before immersion is 1.8 or more.

4. The medical film according to any one of claims 1 to 3, wherein the medical film contains 5 parts by mass or more and 95 parts by mass or less of the biodegradable resin per 100 parts by mass of the crosslinked polymer material.

5. The medical film according to any one of claims 1 to 4, wherein the biodegradable resin is a polymer in which the ratio of structural units derived from glycolic acid to the total mass of the biodegradable resin is 5% by mass or more and 100% by mass or less.

6. The medical film according to any one of claims 1 to 5, having a thickness of 15 μm or more and 500 μm or less.

7. The medical film according to any one of claims 1 to 6, which is an adhesion preventing material.

Citation Information

Patent Citations

  • Money handling device

    JP2023077267A

  • Anti-adhesion material

    WO2011081162A1

  • Laminate

    WO2017164264A1

  • Production method of gel film and gel film

    JP2020139117A

  • Bioabsorbable medical material

    WO2021201150A1